Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2

Raphael Breuer, Izidore Lossos, Reuven Or, Miron Krymsky, Arie Dagan, Shaul Yedgar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The mechanism of bleomycin (Bleo)-induced pulmonary injury is not fully understood. Elevated levels of lung phospholipase A2 (PLA2) have been previously reported following intratracheal (IT) instillation of Bleo, but the role of this enzyme in the pathogenesis of lung injury is not clear.In this pilot study, we have evaluated the effect of a cell impermeable inhibitor of PLA2 (CME) on Bleo-induced pulmonary inflammation in hamsters. Pulmonary injury was induced by a single IT instillation of Bleo (1 unit/0.5 ml saline). Three groups of male Syrian hamsters were evaluated: 1) BLEO-CME animals received IT Bleo and daily intraperitoneal (IP) injections of CME (1 μmole/kg), starting 1 day before IT instillation; 2) BLEO-SAL animals-received IT Bleo and IP injections of saline and 3) SAL-SAL animals - treated with IT and IP administrations of saline. Animals were sacrificed 14 days after IT treatment and lung injury was evaluated histologically by a semiquantitative morphologic index and by a differential cell count of bronchoalveolar lavage fluid. CME treatment significantly ameliorated Bleo-induced lung injury compared to BLEO-SAL animals (P < 0.05). The percentage of neutrophiles in bronchoalveolar lavage fluid was reduced from 17.7 ± 3.2% (mean ± S.E.) in BLEO-SAL group to 7.3 ± 1.7% in BLEO-CME group (P < 0.05), achieving levels comparable to SAL-SAL control animals. These results suggest that treatment with an extracellular PLA2 inhibitor-CME abates Bleo-induced pulmonary injury. This may indicate an active role of PLA2 in the pathogenesis of interstitial pulmonary fibrosis.

Original languageEnglish
JournalLife Sciences
Volume57
Issue number16
DOIs
StatePublished - Sep 8 1995
Externally publishedYes

Fingerprint

Bleomycin
Lung Injury
Animals
Phospholipases A2
Bronchoalveolar Lavage Fluid
Intraperitoneal Injections
Fluids
PLIalpha
Pulmonary Fibrosis
Mesocricetus
Cricetinae
Pneumonia
Neutrophils
Therapeutics
Cell Count
Lung
Enzymes

Keywords

  • bleomycin
  • hamster
  • phospholipase A

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology

Cite this

Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2. / Breuer, Raphael; Lossos, Izidore; Or, Reuven; Krymsky, Miron; Dagan, Arie; Yedgar, Shaul.

In: Life Sciences, Vol. 57, No. 16, 08.09.1995.

Research output: Contribution to journalArticle

Breuer, Raphael ; Lossos, Izidore ; Or, Reuven ; Krymsky, Miron ; Dagan, Arie ; Yedgar, Shaul. / Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2. In: Life Sciences. 1995 ; Vol. 57, No. 16.
@article{7e070b7bb87a4689bd451c6eba01c286,
title = "Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2",
abstract = "The mechanism of bleomycin (Bleo)-induced pulmonary injury is not fully understood. Elevated levels of lung phospholipase A2 (PLA2) have been previously reported following intratracheal (IT) instillation of Bleo, but the role of this enzyme in the pathogenesis of lung injury is not clear.In this pilot study, we have evaluated the effect of a cell impermeable inhibitor of PLA2 (CME) on Bleo-induced pulmonary inflammation in hamsters. Pulmonary injury was induced by a single IT instillation of Bleo (1 unit/0.5 ml saline). Three groups of male Syrian hamsters were evaluated: 1) BLEO-CME animals received IT Bleo and daily intraperitoneal (IP) injections of CME (1 μmole/kg), starting 1 day before IT instillation; 2) BLEO-SAL animals-received IT Bleo and IP injections of saline and 3) SAL-SAL animals - treated with IT and IP administrations of saline. Animals were sacrificed 14 days after IT treatment and lung injury was evaluated histologically by a semiquantitative morphologic index and by a differential cell count of bronchoalveolar lavage fluid. CME treatment significantly ameliorated Bleo-induced lung injury compared to BLEO-SAL animals (P < 0.05). The percentage of neutrophiles in bronchoalveolar lavage fluid was reduced from 17.7 ± 3.2{\%} (mean ± S.E.) in BLEO-SAL group to 7.3 ± 1.7{\%} in BLEO-CME group (P < 0.05), achieving levels comparable to SAL-SAL control animals. These results suggest that treatment with an extracellular PLA2 inhibitor-CME abates Bleo-induced pulmonary injury. This may indicate an active role of PLA2 in the pathogenesis of interstitial pulmonary fibrosis.",
keywords = "bleomycin, hamster, phospholipase A",
author = "Raphael Breuer and Izidore Lossos and Reuven Or and Miron Krymsky and Arie Dagan and Shaul Yedgar",
year = "1995",
month = "9",
day = "8",
doi = "10.1016/0024-3205(95)02116-Z",
language = "English",
volume = "57",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "16",

}

TY - JOUR

T1 - Abatement of bleomycin-induced pulmonary injury by cell-impermeable inhibitor of phospholipase A2

AU - Breuer, Raphael

AU - Lossos, Izidore

AU - Or, Reuven

AU - Krymsky, Miron

AU - Dagan, Arie

AU - Yedgar, Shaul

PY - 1995/9/8

Y1 - 1995/9/8

N2 - The mechanism of bleomycin (Bleo)-induced pulmonary injury is not fully understood. Elevated levels of lung phospholipase A2 (PLA2) have been previously reported following intratracheal (IT) instillation of Bleo, but the role of this enzyme in the pathogenesis of lung injury is not clear.In this pilot study, we have evaluated the effect of a cell impermeable inhibitor of PLA2 (CME) on Bleo-induced pulmonary inflammation in hamsters. Pulmonary injury was induced by a single IT instillation of Bleo (1 unit/0.5 ml saline). Three groups of male Syrian hamsters were evaluated: 1) BLEO-CME animals received IT Bleo and daily intraperitoneal (IP) injections of CME (1 μmole/kg), starting 1 day before IT instillation; 2) BLEO-SAL animals-received IT Bleo and IP injections of saline and 3) SAL-SAL animals - treated with IT and IP administrations of saline. Animals were sacrificed 14 days after IT treatment and lung injury was evaluated histologically by a semiquantitative morphologic index and by a differential cell count of bronchoalveolar lavage fluid. CME treatment significantly ameliorated Bleo-induced lung injury compared to BLEO-SAL animals (P < 0.05). The percentage of neutrophiles in bronchoalveolar lavage fluid was reduced from 17.7 ± 3.2% (mean ± S.E.) in BLEO-SAL group to 7.3 ± 1.7% in BLEO-CME group (P < 0.05), achieving levels comparable to SAL-SAL control animals. These results suggest that treatment with an extracellular PLA2 inhibitor-CME abates Bleo-induced pulmonary injury. This may indicate an active role of PLA2 in the pathogenesis of interstitial pulmonary fibrosis.

AB - The mechanism of bleomycin (Bleo)-induced pulmonary injury is not fully understood. Elevated levels of lung phospholipase A2 (PLA2) have been previously reported following intratracheal (IT) instillation of Bleo, but the role of this enzyme in the pathogenesis of lung injury is not clear.In this pilot study, we have evaluated the effect of a cell impermeable inhibitor of PLA2 (CME) on Bleo-induced pulmonary inflammation in hamsters. Pulmonary injury was induced by a single IT instillation of Bleo (1 unit/0.5 ml saline). Three groups of male Syrian hamsters were evaluated: 1) BLEO-CME animals received IT Bleo and daily intraperitoneal (IP) injections of CME (1 μmole/kg), starting 1 day before IT instillation; 2) BLEO-SAL animals-received IT Bleo and IP injections of saline and 3) SAL-SAL animals - treated with IT and IP administrations of saline. Animals were sacrificed 14 days after IT treatment and lung injury was evaluated histologically by a semiquantitative morphologic index and by a differential cell count of bronchoalveolar lavage fluid. CME treatment significantly ameliorated Bleo-induced lung injury compared to BLEO-SAL animals (P < 0.05). The percentage of neutrophiles in bronchoalveolar lavage fluid was reduced from 17.7 ± 3.2% (mean ± S.E.) in BLEO-SAL group to 7.3 ± 1.7% in BLEO-CME group (P < 0.05), achieving levels comparable to SAL-SAL control animals. These results suggest that treatment with an extracellular PLA2 inhibitor-CME abates Bleo-induced pulmonary injury. This may indicate an active role of PLA2 in the pathogenesis of interstitial pulmonary fibrosis.

KW - bleomycin

KW - hamster

KW - phospholipase A

UR - http://www.scopus.com/inward/record.url?scp=0028823775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028823775&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(95)02116-Z

DO - 10.1016/0024-3205(95)02116-Z

M3 - Article

C2 - 7564888

AN - SCOPUS:0028823775

VL - 57

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 16

ER -